Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olympus Challenges Given Imaging In U.S. Capsule Endoscopy Market

This article was originally published in The Gray Sheet

Executive Summary

Olympus launched its Endo Capsule endoscopy system Sept. 17, making it the second ingestible video camera device for diagnosing small bowel abnormalities to reach the U.S. market

You may also be interested in...



Olympus Builds Minimally Invasive Surgery Line With $1.9 Bil. Gyrus Deal

Olympus will expand its focus on minimally invasive surgical offerings by acquiring electrosurgical instrument maker Gyrus Group under a $1.9 billion deal announced Nov. 19

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel